Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAE0972 plus investigator-choice chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma or nasopharyngeal carcinoma
CTR20244508Phase 3Active
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Dec 2024
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of IAE0972 in head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC), sponsored by SUNHO BioPharmaceutical. Started Dec 2024; status: active.
02
Drugs
IAE0972
03
Conditions
head and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20244508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244508.